ArticleCurrent Alzheimer research2021
Association of Dietary Prebiotic Consumption with Reduced Risk of Alzheimer's Disease in a Multiethnic Population.
Article in Current Alzheimer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Dietary and Supplementation Strategies for Modulating Gut Microbiota: A Narrative Review.Foods (Basel, Switzerland) · 2026Review
- The interplay between gut microbiota and Alzheimer's disease: mechanistic insights from dysbiosis to disease modulation.Metabolic brain disease · 2026Review
- Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics for the Prevention and Management of Alzheimer's Disease: A Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- The Gut-Brain Axis in Alzheimer's Disease: Exploring Microbial Influences and Therapeutic Strategies.Molecular neurobiology · 2025Review
- Unveiling probiotic and prebiotic functional dairy foods: a health beneficial outlook.3 Biotech · 2025Review
- A review on gut microbiota and miRNA crosstalk: implications for Alzheimer's disease.GeroScience · 2025Review
- Gut microbiota-driven neuroinflammation in Alzheimer's disease: from mechanisms to therapeutic opportunities.Frontiers in immunology · 2025Review
- Microbiota-Gut-Brain Axis Dysregulation in Alzheimer's Disease: Multi-Pathway Effects and Therapeutic Potential.Aging and disease · 2024Review
- Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside.Translational neurodegeneration · 2024Review
- Amyloid, Crohn's disease, and Alzheimer's disease - are they linked?Frontiers in cellular and infection microbiology · 2024Review
- The aryl hydrocarbon receptor pathway: a linking bridge between the gut microbiome and neurodegenerative diseases.Frontiers in cellular neuroscience · 2024Review
- Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?Frontiers in pharmacology · 2024Review
- Gut Microbiome in Alzheimer's Disease: from Mice to Humans.Current neuropharmacology · 2024Review
- Gut Microbiota and Alzheimer's Disease: How to Study and Apply Their Relationship.International journal of molecular sciences · 2023Review
- The role of probiotics and prebiotics in modulating of the gut-brain axis.Frontiers in nutrition · 2023Review
- The potential of the gut microbiome for identifying Alzheimer's disease diagnostic biomarkers and future therapies.Frontiers in neuroscience · 2023Review
- Unveiling the neuroprotective potential of dietary polysaccharides: a systematic review.Frontiers in nutrition · 2023Review
- Potential Benefits of Anthocyanins in Chronic Disorders of the Central Nervous System.Molecules (Basel, Switzerland) · 2022Review
- The Potential Role of Gut Microbiota in Alzheimer's Disease: From Diagnosis to Treatment.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThis study aimed to investigate the association between dietary prebiotic intake and risk for Alzheimer's disease (AD).
methodsThis longitudinal study includes 1,837 elderly (≥65 years) participants of a multi-ethnic community-based cohort study who were dementia-free at baseline and had provided dietary information from food frequency questionnaires. Total daily intake of fructan, one of the best-known prebiotics, was calculated based on consumption frequency and fructan content per serving of 8 food items. The associations of daily fructan intake with AD risk were examined using a Cox proportional hazards model, adjusted for cohort recruitment wave, age, gender, race/ethnicity, education, daily caloric intake, and APOE genotype. Effect modification by race/ethnicity, APOE genotype, and gender was tested by including an interaction term into the Cox models, as well as by stratified analyses.
resultsAmong 1,837 participants (1,263 women [69%]; mean [SD] age = 76 [6.3] years), there were 391 incident AD cases during a mean follow-up of 7.5 years (13736 person-years). Each additional gram of fructan intake was associated with 24% lower risk for AD ((95% CI)=0.60-0.97; P =0.03). Additional adjusting for smoking, alcohol consumption, and comorbidity index did not change results materially. The associations were not modified by race/ethnicity, gender, and APOE genotype, although stratified analyses showed that fructan intake was significantly associated with reduced AD risk in Hispanics but not in non-Hispanic Blacks or Whites.
conclusionHigher dietary fructan intake is associated with a reduced risk of clinical Alzheimer's disease among older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.